Nivolumab (Nivo), an anti-PD-1 antibody, has demonstrated considerable promise in NSCLC treatment by blocking the interaction of PD-1 with PD-L1 or PD-L2 [13]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.